Join us for 60 minute webinar in the safety of your home or office.
The introduction of immunotherapy and PD-L1 IHC testing delivered many successes in clinical outcomes of highly aggressive tumors, but also created series of challenges for pathologists and pathology laboratories where PD-L1 IHC testing is being performed. Oncologists are also challenged in regard to proper biomarker selection for any given purpose.
This presentation focuses on the multifaceted issues related to currently widely used and also emerging PDL1 immunohistochemistry (IHC) assays in Canada. This presentation will address various aspects of so-called assay "interchangeability" and it will also propose abbreviated algorithm for pathologist and pathology laboratories to guide their strategies and assay selection for various purposes. It will also emphasize the role of various spheres of assay validation including clinical, diagnostic, and technical validation highlighting the need for team approach to test development for various different purposes (drugs, diseases) and ongoing quality assurance.
Pathologists, Residents, Medical Students, Laboratory technologists in IHC laboratories
At the end of the meeting participants will be able to:
Identify which PD-L1 IHC assays are "fit-for-purpose".
Use specific criteria to identify which PD-L1 assays are interchangeable for any given specific purpose.
Distinguish between different spheres of validation of PD-L1 assays.
Distinguish between PD-L1 antibody and PD-L1 assay.
CanMEDS Roles: Medical Expert (the integrating role), Health Advocate
Speaker: Emina Emilia Torlakovic, MD, PhD, FCAP
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1.0 hour (credits are automatically calculated).